Skip to main content

VolitionRx Acquires Nucleosome Analysis IP from Chroma Therapeutics

NEW YORK (GenomeWeb) – Belgian diagnostics firm VolitionRx said today that it has acquired a patent family around nucleosome analysis in cancer from Chroma Therapeutics.

The patent family, WO 2005/019826, was originally filed by UK-based Chroma and exclusively licensed to VolitionRx.

The IP covers the detection of histone modifications in cell-free nucleosomes from circulating cancer cells. VolitionRx, based in Namur, owns other patents covering the analysis of nucleosomes and chromatin fragment structures. The company is developing blood-based diagnostic tests for cancer and other conditions.

"Having all the core Nucleosomics IP completely royalty free is a very positive outcome for the retention of the value we aim to create for our shareholders," said VolitionRx CEO Cameron Reynolds in a statement.

The company, which raised $8.5 million in an initial public offering earlier this month, plans to market its diagnostic products in Europe first, followed by the US and other regions.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.